Tonix Pharmaceuticals Holding Corp reports results for the quarter ended June 30 - Earnings Summary
14/08/2025 22:01
Tonix Pharmaceuticals Holding Corp TNXP.OQ reported a quarterly adjusted loss of $3.86 per share for the quarter ended June 30, higher than the same quarter last year, when the company reported EPS of $-1,928.00. The mean expectation of two analysts for the quarter was for a loss of $3.21 per share. Wall Street expected results to range from $-3.51 to $-2.92 per share. Revenue fell 9.5% to $2.00 million from a year ago; analysts expected $2.43 million. Tonix Pharmaceuticals Holding Corp's reported EPS for the quarter was a loss of $3.86. The company reported a quarterly loss of $28.27 million. Tonix Pharmaceuticals Holding Corp shares had risen by 71.1% this quarter and gained 86.7% so far this year. FORECAST CHANGES The mean earnings estimate of analysts had risen by about 52.9% in the last three months. In the last 30 days, there have been no negative revisions of earnings estimates RECOMMENDATIONS The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy," no "hold" and no "sell" or "strong sell." The average consensus recommendation for the pharmaceuticals peer group is also "buy" Wall Street's median 12-month price target for Tonix Pharmaceuticals Holding Corp is $65.00, about 5.3% above its last closing price of $61.57 This summary was machine generated from LSEG data August 14 at 09:00 p.m. UTC. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
| QUARTER ENDING | ESTIMATE | ACTUAL | BEAT, MET, MISSED |
| Jun. 30 2025 | -3.21 | -3.86 | Missed |
| Mar. 31 2025 | -3.23 | -2.84 | Beat |
| Dec. 31 2024 | -3.87 hundred | -9.77 | Beat |
| Sep. 30 2024 | -2.93 hundred | -23.00 | Beat |
Recent news on Tonix Pharmaceuticals Holding
See all newsBrief: Tonix Pharmaceuticals Says Dr. Reddy's Files ANDA With Paragraph IV Patent Certification For Generic Tonmya
Brief: Tonix Pharmaceuticals Announces Second Major Managed Medicare Payer Agreement For Tonmya®
Tonix Pharmaceuticals Holding Corp. reports results for the quarter ended June 30 - Earnings Summary
Tonix Q2 revenue rises sharply on TONMYA launch
Tonix Pharmaceuticals Holding Corp. expected to post a loss of $2.70 a share - Earnings Preview